Purpose: [ 177 Lu]Lu-PSMA-617 radioligand therapy ( 177 Lu-PSMA) is a novel treatment
for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to …

Background PSMA-PET is a novel imaging modality for the staging of prostate cancer (PCa).
While there are several PSMA ligands available, F-18-PSMA-1007 is particularly of interest …

Accurate assessment of lymph node (LN) metastases in prostate cancer (PCa) patients is
critical for prognosis and patient management. Both prostate-specific membrane antigen (…

Purpose Incomplete resection of prostate cancer (PCa) results in increased risk of disease
recurrence. Combined fluorescence-guided surgery with tumor-targeted photodynamic …

Prostate-specific membrane antigen (PSMA)–targeted radioguided surgery (RGS) aims to
optimize the peroperative detection and removal of PSMA-avid lymph node (LN) metastases (…

Recent developments in (molecular) imaging technologies have led to significant changes
in diagnostic, staging, and therapeutic processes in prostate cancer (PCa). The recent …

Purpose In biopsy naïve men suspected for prostate cancer (PCa), it is uncertain how a risk-calculator
and bi-parametric (bp) MRI should be combined to decide on prostate biopsy, …

Detection of lymph node (LN) metastases in prostate cancer (PCa) is pivotal for accurate
staging and determining treatment options. To date, the reference standard for nodal staging is …

Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's
Letter to the Editor re: Melline GM Schilham, Mark Rijpkema, Tom Scheenen, et al. How …

Re: Melline GM Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging
Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the …